At a glance
ClinicalIndex Comparison Record- ✓Metastatic or unresectable gastric carcinoma
- ✓Measurable disease present
- ✓Performance status Karnofsky 70-100%
- ✓No prior chemotherapy
- ✕Brain metastases
- ✕History of bleeding disorders
- ✕History of peptic ulceration or gastrointestinal bleeding
- ✕Active infection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Combination Trial of Bryostatin-1 and Cisplatin in the Treatment of Metastatic Gastric Cancer
In Brief
A Phase 2 clinical trial evaluating bryostatin 1, cisplatin, and 1 other intervention for Stage III Gastric Cancer and Stage IV Gastric Cancer. Completed, enrolled 12 participants across 1 site.
Detailed Summary
Phase II trial to study the effectiveness of bryostatin 1 and cisplatin in treating patients who have metastatic or unresectable stomach cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bryostatin 1 may increase the effectiveness of cisplatin by making tumor cells more sensitive to the drug. Combining cisplatin with bryostatin 1 may kill more tumor cells.
Study Details
Timeline
Interventions
Given IV
Given IV
Correlative studies